Focused On-demand Library for Na(+)/citrate cotransporter

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Sodium-coupled citrate transporter; Sodium-dependent citrate transporter; Solute carrier family 13 member 5

Alternative UPACC:

Q86YT5; B3KXR0; B7Z4P2; B7ZLB4; F8W7N2; Q6ZMG1


The Na(+)/citrate cotransporter, also known as Sodium-coupled citrate transporter or Solute carrier family 13 member 5, plays a pivotal role in cellular metabolism. It facilitates the high-affinity transport of citrate into cells, a key component in energy production and biosynthetic pathways. This protein operates in a Na(+)-dependent manner, primarily recognizing the trivalent form of citrate at physiological pH, and exhibits a lower affinity for succinate.

Therapeutic significance:

The protein's involvement in Developmental and epileptic encephalopathy 25, with amelogenesis imperfecta, underscores its clinical importance. Understanding the role of Na(+)/citrate cotransporter could open doors to potential therapeutic strategies for this severe neurological disorder, offering hope for targeted interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.